Haic+tae + tislelizumab + surufatinib for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Sep 2022: Trial started, NCT06239532
  2. 2 Feb 2024: Trial registered, NCT06239532

The trials

NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

State
Under way
Phase
Phase 2
People
28 taking part
Started
27 Sep 2022
Primary completion
31 Dec 2024
Arms
TAE+HAIC+Tislelizumab+Surufatinib
Results
None posted
  1. 27 Sep 2022: Trial started
  2. 2 Feb 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.